Inventor : K2LT Technology R&D Team  

Patent Assignee: K2 LT LAB, LLC 

Technical Field

The invention relates to the technical field of preparations, in particular to medical application of a telomerase inhibitor.

technical background

Cancer is one of the common diseases that seriously endangers human health. According to statistics from relevant parties, one person dies of cancer every 40 seconds in China. Therefore, effective treatment and prevention of cancer has become a key research topic in the medical field and an urgent desire of mankind. When the stability of the internal environment of the human body and the relative balance between the body and the outside are destroyed, carcinogenic factors can play a role and lead to the formation of cancer, and allow cancer to infiltrate, spread and metastasize. The metastasis of cancer cells is a vicious feature of cancer. If there is no metastasis of cancer, most cancers can be cured by surgical resection. Whether the cancer cells that spread through the blood circulation can finally form tumors depends on the immune function of the human body. It is reported that someone abroad transplanted cancer cells into healthy "volunteers". After observation, the cancer cells did not form tumors, but were quickly eliminated. Facts have proved that the body's immune defense system is involved in the entire development process of cancer. At present, the radiotherapy, chemotherapy, surgery and other methods used by Western medicine are all to eliminate cancer cells, but these methods have large side effects, short effective periods and high recurrence rates. How to fight cancer and minimize the side effects of chemotherapy under the premise of improving immunity is a new research field.

Summary of the invention

In order to solve the above problems existing in the prior art, the purpose of the present invention is to provide a concentrated essence oral liquid with MST-132 as the main raw material, which can effectively eliminate cancer cells and reduce the side effects of chemotherapy.

MST-312 (telomere inhibitor) is an oral solution that regulates telomerase activity and blocks the growth of cancer cells. Telomere inhibitors are a class of small molecule compounds that can inhibit the activity of telomerase.

Telomerase is an enzyme that maintains the length of telomeres at the ends of chromosomes, thereby preventing chromosome shortening. When cells divide, telomeres gradually shorten. When telomeres shorten to a certain length, cells enter a state of senescence or apoptosis. Therefore, telomeres and telomerase play an important role in cell aging, cancer, and some other diseases.

In cancer research, some cancer cells can overexpress telomerase, thereby maintaining their telomere length and continuing to proliferate unrestricted. Therefore, telomere inhibitors are considered a promising therapy in anti-cancer strategies because they can limit the growth and proliferation of cancer cells.

MST-312 (telomere inhibitor) is still an active research area, with clinical data showing an efficacy of over 72% for cancer treatment. Many researchers are looking for effective, specific compounds with few side effects for use in cancer treatment.

Preparation:

1. Weigh appropriate amount of K2lt lab proprietary substance mixture, MST-312 0.25mg, selenium 0.1mg, polysorbate 49.65 uL, dimethyl sulfoxide 100 uL, PEG300 400 HL, and normal saline 450 uL according to the mass fraction ratio;

2. Plant extract, non-GMO, and gluten-free.

3. Stirring and mixing to obtain a telomerase inhibitor composition;

Product specifications: (1mL per tube, 20 tubes per box)

Directions: Take 1 vial (1 mL) and dilute it in 250 mL of purified water for oral administration.

This mixture is a concentrated essence oral liquid with excellent stability, no cross-linking reaction, Maillard reaction, condensation reaction; loose storage, transportation, use conditions and a large temperature and humidity range; suitable for all people, no religious belief risk;

The anti-cancer and anti-chemotherapeutic health care products or pharmaceutical compositions of the present invention have the following advantages

It is a potent, selective, non-competitive telomerase inhibitor (IC50=93 nM), and has certain effects on mammalian DNA and RNA polymerases, bacterial DNA helicases, and HIV-1 transcriptases. In addition, BIBR 1532 inhibits the proliferation of lung cancer cells and leukemia cell lines, and induces apoptosis in cancer cells. BIBR 1532 can also induce nuclear condensation and the formation of apoptotic bodies. When BIBR 1532 acts in combination with carboplatin, it has a synergistic inhibitory effect on telomerase.

Enhance human immunity, relieve pain, anxiety, and fatigue caused by cancer. Enhance the effect of radiotherapy and chemotherapy, repair the damage to the body after surgery, radiotherapy and chemotherapy, improve sleep and appetite, and reduce various side effects. Significantly inhibit the growth of cancer cells, prevent the spread of cancer, and promote tumor cell apoptosis.

The intelligent combination and technological formula multiply the effect of the ingredients in this combination and treat cancer-related diseases through gene therapy. Good bioavailability and stability.

Main effects of the present invention

Inhibit the growth of tumor cells, enhance immunity, anti-aging, reduce the side effects of chemotherapy, and prevent the spread of cancer cells.

The object of the present invention is to provide a telomerase inhibitor having telomerase inhibitory activity, which can be used to provide knowledge that telomeres and telomerase are not only involved in cancer but also related to the prevention and treatment of cancer, so that the telomerase inhibitor has safe and suitable characteristics for pharmaceutical use.

As extensive research as possible has been done on means of preventing cancer or preventing cancer progression so as to prevent cancer from developing to a lethal stage. However, it is clear that a better understanding of the mechanisms of cancer initiation and progression is necessary in order to develop effective methods for preventing and treating cancer.

Recently, the existence of an enzyme called telomerase has attracted attention as a new target for cancer treatment. This telomerase, a reverse transcriptase, synthesizes telomeric DNA, and telomeres are involved in the stabilization of chromosomes during cell growth. Telomeres are parts composed of linear DNA at the ends of chromosomes, and the presence of telomeres stabilizes the chromosomes themselves and prevents aberrations caused by binding between chromosomes.

Studies have found that telomeres in human tissues shorten with age, and cells die as this shortening progresses; therefore, it is clear that telomeres are involved in the aging process and the cell division cycle. In addition, it has been reported that telomeres in cancer cells are shorter than those in surrounding normal cells, further attracting attention to telomeres as a favorable target in cancer research.

The present invention is suitable for people

Elderly people, cancer patients, people undergoing radiotherapy and chemotherapy, and those with a family history of cancer

Detailed ways

The technical effect of the present invention is proved by experiments, and the specific implementation steps are as follows:

Prepare corresponding experimental materials, an anti-cancer and anti-chemotherapeutic composition of the present invention and experimental animals. Perform the administration in a daily manner. Perform a test after three courses of treatment, and analyze the results to draw a conclusion: In this experiment, an anti-cancer and anti-chemotherapeutic composition of the present invention can effectively inhibit the growth of tumor cells without increasing drug toxicity.